Data sourced from ClinicalTrials.gov (NIH registry) Updated weekly IRB-supervised studies only
Home/MI/Muskegon
Updated July 2026 from ClinicalTrials.gov

Paid Clinical Trials in Muskegon, MI

Studies commonly pay $75 to $4,500 per completed study

61 clinical trials are currently recruiting participants within 30 miles of Muskegon. Listings below come straight from the official NIH registry, alongside the area's top-rated research centers with real Google reviews.

61studies recruiting
3+research centers nearby
3condition categories
Live from the NIH registry

Studies recruiting near Muskegon right now

Top 25 of 61 recruiting studies, sorted by proximity — each links to its official registry page

BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study

Multiple conditions Phase 2 Interventional 150 participants sought
Trinity Health Muskegon Hospital — Muskegon, Michigan (0.6 mi) · Sponsor: National Cancer Institute (NCI)
See eligibility & contact on ClinicalTrials.gov (NCT05136196)

Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial

Plasma Cell Myeloma, RISS Stage I Plasma Cell Myeloma Phase 3 Interventional 1,450 participants sought
Trinity Health Muskegon Hospital — Muskegon, Michigan (0.6 mi) · Sponsor: ECOG-ACRIN Cancer Research Group
See eligibility & contact on ClinicalTrials.gov (NCT04566328)

Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma

Classic Follicular Lymphoma, Follicular Lymphoma With Unusual Cytological Features Phase 3 Interventional 600 participants sought
Trinity Health Muskegon Hospital — Muskegon, Michigan (0.6 mi) · Sponsor: National Cancer Institute (NCI)
See eligibility & contact on ClinicalTrials.gov (NCT06337318)

Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer

Advanced Endometrial Carcinoma, Recurrent Endometrial Carcinoma Phase 3 Interventional 255 participants sought
Trinity Health Muskegon Hospital — Muskegon, Michigan (0.6 mi) · Sponsor: National Cancer Institute (NCI)
See eligibility & contact on ClinicalTrials.gov (NCT07198074)

A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer

Ovarian Carcinoma N/A Interventional 1,956 participants sought
Trinity Health Muskegon Hospital — Muskegon, Michigan (0.6 mi) · Sponsor: NRG Oncology
See eligibility & contact on ClinicalTrials.gov (NCT04251052)

Thoracotomy Versus Thoracoscopic Management of Pulmonary Metastases in Patients With Osteosarcoma

Metastatic Malignant Neoplasm in the Lung, Metastatic Osteosarcoma Phase 3 Interventional 62 participants sought
Trinity Health Muskegon Hospital — Muskegon, Michigan (0.6 mi) · Sponsor: Children's Oncology Group
See eligibility & contact on ClinicalTrials.gov (NCT05235165)

Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics

Breast Carcinoma, Colorectal Carcinoma N/A Observational 2,000 participants sought
Trinity Health Muskegon Hospital — Muskegon, Michigan (0.6 mi) · Sponsor: Wake Forest University Health Sciences
See eligibility & contact on ClinicalTrials.gov (NCT06418204)

De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)

Stage I Breast Cancer Phase 3 Interventional 1,670 participants sought
Trinity Health Muskegon Hospital — Muskegon, Michigan (0.6 mi) · Sponsor: NRG Oncology
See eligibility & contact on ClinicalTrials.gov (NCT04852887)

Cognitive Training for Cancer Related Cognitive Impairment in Breast Cancer Survivors

Breast Cancer, Cognitive Impairments N/A Interventional 386 participants sought
Trinity Health Muskegon Hospital — Muskegon, Michigan (0.6 mi) · Sponsor: NRG Oncology
See eligibility & contact on ClinicalTrials.gov (NCT05896189)

Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas

Intracranial Meningioma, Recurrent Meningioma Phase 2 Interventional 124 participants sought
Trinity Health Muskegon Hospital — Muskegon, Michigan (0.6 mi) · Sponsor: Alliance for Clinical Trials in Oncology
See eligibility & contact on ClinicalTrials.gov (NCT02523014)

Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer

Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8 Phase 3 Interventional 3,680 participants sought
Trinity Health Muskegon Hospital — Muskegon, Michigan (0.6 mi) · Sponsor: National Cancer Institute (NCI)
See eligibility & contact on ClinicalTrials.gov (NCT06058377)

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

Lung Non-Small Cell Carcinoma, Lung Non-Small Cell Squamous Carcinoma Phase 3 Interventional 1,210 participants sought
Trinity Health Muskegon Hospital — Muskegon, Michigan (0.6 mi) · Sponsor: National Cancer Institute (NCI)
See eligibility & contact on ClinicalTrials.gov (NCT04267848)

ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab

Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8 Phase 3 Interventional 1,524 participants sought
Trinity Health Muskegon Hospital — Muskegon, Michigan (0.6 mi) · Sponsor: Alliance for Clinical Trials in Oncology
See eligibility & contact on ClinicalTrials.gov (NCT06876714)

Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer

Previously Treated Non-Small Cell Lung Cancer Phase 2, Phase 3 Interventional 10,000 participants sought
Trinity Health Muskegon Hospital — Muskegon, Michigan (0.6 mi) · Sponsor: SWOG Cancer Research Network
See eligibility & contact on ClinicalTrials.gov (NCT03851445)

Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial

Advanced Lung Non-Small Cell Carcinoma, Stage IIIB Lung Cancer AJCC v8 Phase 3 Interventional 304 participants sought
Trinity Health Muskegon Hospital — Muskegon, Michigan (0.6 mi) · Sponsor: National Cancer Institute (NCI)
See eligibility & contact on ClinicalTrials.gov (NCT06096844)

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

Multiple conditions N/A Observational 2,000 participants sought
Trinity Health Muskegon Hospital — Muskegon, Michigan (0.6 mi) · Sponsor: Alliance for Clinical Trials in Oncology
See eligibility & contact on ClinicalTrials.gov (NCT05334069)

A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2

Urothelial Carcinoma Phase 2 Interventional 372 participants sought
The Cancer & Hematology Centers — Norton Shores, Michigan (4.1 mi) · Sponsor: Seagen, a wholly owned subsidiary of Pfizer
See eligibility & contact on ClinicalTrials.gov (NCT04879329)

Collection and Storage of Tissue and Blood Samples From Patients With Cancer

Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm N/A Observational 5,000 participants sought
Trinity Health Muskegon Hospital — Muskegon, Michigan (0.6 mi) · Sponsor: National Cancer Institute LAO
See eligibility & contact on ClinicalTrials.gov (NCT02474160)

Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study

Muscle Invasive Bladder Urothelial Carcinoma, Muscle Invasive Renal Pelvis Urothelial Carcinoma Phase 2, Phase 3 Interventional 992 participants sought
Trinity Health Muskegon Hospital — Muskegon, Michigan (0.6 mi) · Sponsor: National Cancer Institute (NCI)
See eligibility & contact on ClinicalTrials.gov (NCT05987241)

Study to Test OBI-3424 in Patients With T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LBL)

Recurrent T Acute Lymphoblastic Leukemia, Refractory T Acute Lymphoblastic Leukemia Phase 1, Phase 2 Interventional 67 participants sought
Trinity Health Muskegon Hospital — Muskegon, Michigan (0.6 mi) · Sponsor: SWOG Cancer Research Network
See eligibility & contact on ClinicalTrials.gov (NCT04315324)

A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab

Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8 Phase 3 Interventional 1,875 participants sought
Trinity Health Muskegon Hospital — Muskegon, Michigan (0.6 mi) · Sponsor: National Cancer Institute (NCI)
See eligibility & contact on ClinicalTrials.gov (NCT05675410)

Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer

Clear Cell Renal Cell Carcinoma, Renal Cell Carcinoma (RCC) Phase 3 Interventional 1,040 participants sought
Trinity Health Muskegon Hospital — Muskegon, Michigan (0.6 mi) · Sponsor: Alliance for Clinical Trials in Oncology
See eligibility & contact on ClinicalTrials.gov (NCT06661720)

Lanreotide Versus Placebo Before Surgery to Prevent a Surgical Complication Called a Pancreatic Fistula

Pancreatic Carcinoma, Pancreatic Neoplasm Phase 3 Interventional 274 participants sought
Trinity Health Muskegon Hospital — Muskegon, Michigan (0.6 mi) · Sponsor: SWOG Cancer Research Network
See eligibility & contact on ClinicalTrials.gov (NCT06807437)

S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity

Cardiotoxicity, HER2/Neu Positive Phase 3 Interventional 491 participants sought
Trinity Health Muskegon Hospital — Muskegon, Michigan (0.6 mi) · Sponsor: SWOG Cancer Research Network
See eligibility & contact on ClinicalTrials.gov (NCT03418961)

Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

Breast Cancer Phase 3 Interventional 3,960 participants sought
Trinity Health Muskegon Hospital — Muskegon, Michigan (0.6 mi) · Sponsor: NRG Oncology
See eligibility & contact on ClinicalTrials.gov (NCT05879926)
Google-rated

Top-rated research centers in Muskegon

Dedicated clinical research sites near you — with their real Google ratings, reviews and contact details

West Michigan Clinical Research Center

2093 Health Dr SW Ste 201, Wyoming, MI 49519
(616) 328-5344

Center for Clinical Research at WMed

★ 5.0 (1 reviews)
1000 Oakland Dr, Kalamazoo, MI 49008
(269) 337-4264
"I would like overnight clinic study paid. Kalamazoo"
— Terri Dee Little, 5★

The Cancer & Hematology Centers

★ 4.8 (368 reviews)
6425 Harvey St, Norton Shores, MI 49444
(231) 737-3469
"When you get checked in for your appointment make sure that if you pay you get a receipt. There was only 1 month I did not pay because of a lost car…"
— Rebecca Provatas, 1★

Clinical trials in Muskegon: what's recruiting

The Muskegon area currently has 61 studies open to new participants, according to the ClinicalTrials.gov registry maintained by the U.S. National Institutes of Health. Among the studies closest to Muskegon, the most active research areas are:

  • Cancer & Oncology24 studies
  • Liver & Kidney3 studies
  • Heart & Vascular1 studies

Every listing shows the study phase, the recruiting site and its distance from Muskegon, and links to the official registry page where eligibility criteria and study contacts are published. Compensation is set by each sponsor: industry surveys report typical payments of $75 to $4,500 per completed study, with short observational studies at the low end and multi-visit or overnight Phase 1 studies at the high end.

How to enroll in a paid study in Muskegon

Start with a study whose condition matches your profile — or a healthy-volunteer study if you have no diagnosis. Contact the research site through the registry page, complete a short phone screen, then attend an in-person screening visit. If you qualify, the study team walks you through the informed consent document, which details every procedure, risk and payment before you commit. You can withdraw at any point, and enrollment is always free.

Muskegon participants can also register with the dedicated research centers listed above — many maintain volunteer databases and call when a matching study opens — or sign up for our email alert below to hear when a new study starts recruiting within 30 miles of your ZIP code.

Frequently asked questions

How much do paid clinical trials in Muskegon pay?
Compensation varies by study length, procedures and overnight stays. Industry surveys report typical payments from $75 to $4,500 per completed study, with simple observational studies at the low end and multi-week inpatient Phase 1 studies at the high end. Each listing's study team will confirm the exact amount before you enroll.
Are clinical trials in Muskegon safe?
Every trial on this page is registered on ClinicalTrials.gov, the official NIH registry, and is overseen by an Institutional Review Board (IRB). Before joining you receive an informed consent document detailing procedures, risks and compensation. Participation is voluntary and you can withdraw at any time.
How do I join a study in Muskegon, MI?
Pick a study that matches your profile, contact the research site (or apply through the study links on this page), pass a phone pre-screen, then attend an in-person screening visit. If you qualify, you review and sign the informed consent and the study begins. The process typically takes 1-3 weeks.
Is compensation for clinical trials taxable?
In the U.S., clinical trial compensation is generally considered taxable income, and research sites may issue a 1099 form for payments above $600 in a year. Reimbursements for travel or meals are typically treated differently. Consult a tax professional for your situation.
Can I be in more than one clinical trial at a time?
Generally no — most studies exclude participants currently enrolled in another trial, and paid Phase 1 studies enforce a washout period (often 30 days or more) between studies. Frequent healthy volunteers in Muskegon typically complete one or two studies per year.

Paid clinical trials near Muskegon

Other metros within reach

Grand Rapids, MI455 Kalamazoo, MI109 South Bend, IN113 Elkhart, IN113 Milwaukee, WI693 Lansing, MI185 Chicago, IL2,449 Round Lake Beach, IL455

More of MI

South Lyon1,315 Detroit1,179 Ann Arbor1,179 Grand Rapids455 Lansing185 Flint181 Kalamazoo109

New paid studies open every week

Get an email when a new clinical trial starts recruiting within 30 miles of your ZIP code. No spam — only real studies from the NIH registry.

By subscribing you agree to receive study alert emails. Unsubscribe anytime in one click.

Get free trial alerts